Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMD) Notes Payables (2023 - 2025)

Baird Medical Investment Holdings has reported Notes Payables over the past 3 years, most recently at $10.4 million for Q4 2025.

  • For Q4 2025, Notes Payables fell 35.47% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $10.4 million, down 35.47%, while the annual FY2025 figure was $10.4 million, 35.47% down from the prior year.
  • Notes Payables for Q4 2025 was $10.4 million at Baird Medical Investment Holdings, down from $14.0 million in the prior quarter.
  • Over five years, Notes Payables peaked at $16.2 million in Q4 2024 and troughed at $8.2 million in Q4 2023.
  • A 3-year average of $12.2 million and a median of $12.2 million in 2025 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: surged 97.96% in 2024 and later crashed 35.47% in 2025.
  • Year by year, Notes Payables stood at $8.2 million in 2023, then surged by 97.96% to $16.2 million in 2024, then crashed by 35.47% to $10.4 million in 2025.
  • Business Quant data shows Notes Payables for BDMD at $10.4 million in Q4 2025, $14.0 million in Q2 2025, and $16.2 million in Q4 2024.